Source: Annual Congress 2005 - Biological and treatment aspects of tuberculosis
Disease area: Respiratory infections

Abstract

Aim: to find and to evaluate the side effects (SE) that occur to the patients who receive treatment for MDR tuberculosis.
Study: 1 year (2004) prospective, accomplished by clinical and biological examination and questionnaires.
398 patients have been hospitalized in this period of time. 52 cases of these, were drug resistant tuberculosis; 81% were male (mean age 58, smokers 92%), 19% - female (mean age: 43, smokers 72%). Patients with resistance to at least one drug have been examined, 63% of these had MDR.
The patients‘ treatment was conducted by using individualized treatment regimens (ITR) with 2^nd-line anti-TB drugs (Amikacin, Kanamycin, Fluoroquinolones, Cycloserin, Prothionamid). ITR included 3^rd-line drugs (Amoxicillin/Clavulanic acid, Clarithromycin) to the patients who had MDR resistant to 4 or more anti-TB drugs.
We‘ve performed clinical and biological investigation and we‘ve asked the patients to fill up questionnaires.
Results: SE were recorded for n=32(62%) patients. These were: aplastic anemia and leukopenia (n=3), renal failure (n=2), Stevens-Johnson syndrome (n=3), hearing disturbances to loss (n=7), nausea and vomiting (n=11), diarrhea (n=5),dizziness(n=8) and other (n=9).
Patients have presented 1 or more SE, which were more common among women than men, older than younger (age adjusted).
Discontinuance of treatment, curative or symptomatic medication were administrated.
Conclusion: Treatment‘s SE in MDR tuberculosis patients occurred more commonly among women and among older patients. Is very important to know the SE, in order to prevent or cure, but mostly to prevent discontinuance of treatment.

Rating:

Share or cite this content

Citations should be made in the following way:
I. G. Stoica (Bucharest, Romania). Treatment‘s side effects in MDR tuberculosis patients. Eur Respir J 2005; 26: Suppl. 49, 2905

Member's Comments

Ion-Gabriel Stoica - 31.05.2014 22:34
Very interesting!

Related content which might interest you: Comorbidome in multidrug-resistant tuberculosis patients Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Second and third line anti-tuberculosis drug's side effects during the treatment of patients with multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 555s Year: 2003 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 The clinical features and treatment results of cases with multidrug resistant pulmonary tuberculosis Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis Year: 2004 Prevalence of MDR and XDR tuberculosis among patients with failure of re-treatment course Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Multidrug resistant tuberculosis in non HIV patients Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001 Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Treatment results of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005 Characteristics of the cases with primary multidrug resistance pulmonary tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Intracraniale multiple tuberculomas in patients with MDR TB Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 Drug resistance profiles of mycobacterium tuberculosis isolates in MDR pulmonary tuberculosis from a high burden developing country Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) with different pattern of resistance Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004 Short course of chemotherapy of multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004 Outcomes of patients with multidrug resistant tuberculosis Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003 Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Lipid profile in patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 361s Year: 2002 Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012